VRTX — Vertex Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $125.28bn
- $119.83bn
- $9.87bn
- 86
- 18
- 85
- 67
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4,163 | 6,206 | 7,574 | 8,931 | 9,869 |
Cost of Revenue | |||||
Gross Profit | 3,615 | 5,469 | 6,670 | 7,850 | 8,607 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2,965 | 3,349 | 4,792 | 4,623 | 6,037 |
Operating Profit | 1,198 | 2,856 | 2,782 | 4,307 | 3,832 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1,395 | 3,117 | 2,730 | 4,232 | 4,380 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1,177 | 2,712 | 2,342 | 3,322 | 3,620 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 1,177 | 2,712 | 2,342 | 3,322 | 3,620 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1,177 | 2,712 | 2,342 | 3,322 | 3,620 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 4.51 | 10.3 | 9.01 | 12.9 | 15.9 |